Psyence BioMed Ltd. said Friday that its executive leadership team will travel to the United States to advance ibogaine research and manufacturing [1].
The move signals a push to standardize the production of nature-derived psychedelic compounds. By focusing on Good Manufacturing Practice (GMP) standards, the company aims to transition ibogaine from experimental use toward regulated, medical-grade pharmaceutical applications [1], [3].
Based in New York, the company's strategic engagement initiative focuses on the research, development, and supply of GMP-quality ibogaine [1], [2]. The leadership team is scheduled to travel in the coming weeks to meet with various stakeholders [1], [2].
The company said the primary goals of the trip are to engage with U.S. regulators, potential partners, and investors [1], [3]. This engagement is intended to facilitate the scaling of manufacturing processes and ensure that the compounds meet the rigorous safety and quality standards required for clinical use [1], [3].
Psyence BioMed, which trades on the Nasdaq under the symbol PBM, specializes in the development of psychedelic compounds derived from natural sources [1], [2]. The company's focus on ibogaine is part of a broader effort to utilize these compounds in therapeutic settings [3].
While the company did not specify the exact number of executives traveling, the initiative is described as a core component of its current growth strategy [1], [2]. The focus on the U.S. market reflects the region's role as a hub for both biotechnology investment and regulatory oversight for new drug applications [1], [3].
“The company aims to transition ibogaine from experimental use toward regulated, medical-grade pharmaceutical applications.”
The shift toward GMP-grade manufacturing is a critical step for any biopharmaceutical company seeking FDA approval. By engaging directly with U.S. regulators and investors, Psyence BioMed is attempting to move ibogaine out of the 'underground' or niche research category and into a formal clinical pipeline, which requires strict adherence to manufacturing quality standards to ensure patient safety and dosage consistency.
